An act to add Sections 1367.047, 1367.048, and 1367.049 1367.047 and 1367.048 to the Health and Safety Code, and to add Sections 10144.521, 10144.522, and 10144.523 10144.521 and 10144.522 to the Insurance Code, relating to health care coverage.
AB 669 would change how health plans and health insurers review coverage for substance use disorder treatment beginning January 1, 2027. For in-network inpatient or residential treatment, the bill bars concurrent or retrospective medical-necessity review for the first 28 days of a treatment episode, while allowing concurrent review after day 29. It also limits how often plans or insurers may re-review continued inpatient or residential care after the first 28 days, requires expedited notice and appeal rights if coverage is denied, and generally requires continued coverage for 24 hours after an adverse appeal decision. The bill also requires discharge planning using ASAM criteria and says treatment decisions must be based on the enrollee’s physician and nationally recognized placement criteria.
The bill also extends similar protections to outpatient substance use disorder services. For outpatient services at certified programs, it generally prohibits concurrent or retrospective utilization review, with a specific carve-out for the first 28 days of intensive outpatient or partial hospitalization services, which may be subject to prior authorization but not retrospective review. For day 29 and beyond of those services, concurrent or retrospective review may resume under specified standards. In addition, the bill prohibits prior authorization or other prospective utilization management for medically necessary outpatient prescription drugs used to treat substance use disorder when prescribed by the enrollee’s physician or psychiatrist.
AB 669 would amend both the Health and Safety Code and the Insurance Code, applying its requirements to Knox-Keene health care service plans and to health insurers. It would not apply to Medi-Cal behavioral health delivery systems or Medi-Cal managed care plans. Because violations by health care service plans could be treated as crimes under existing law, the bill is described as creating a state-mandated local program, though it also states that no reimbursement is required. The bill is framed as a coverage and utilization-management reform rather than a benefit-expansion mandate, because it preserves the underlying requirement that treatment be medically necessary.
The overall sentiment reflected in the voting history appears generally supportive of the bill’s policy goals, especially in the Assembly, where it passed third reading by a wide margin. Committee votes were also largely favorable, including unanimous or near-unanimous support in earlier hearings. At the same time, the bill was later amended in the Senate and ultimately held under submission, suggesting unresolved fiscal, implementation, or policy concerns at the committee level. The absence of committee transcript excerpts limits insight into the specific arguments made in discussion.
The main points of contention are likely the bill’s restrictions on utilization management, the operational impact on plans and insurers, and the scope of the appeal and discharge protections. Supporters would likely view the bill as reducing barriers to evidence-based addiction treatment and preventing premature treatment interruptions, while opponents or skeptics may be concerned about reduced plan oversight, increased costs, and the possibility of longer or more expensive stays. The bill’s exceptions for Medi-Cal and its continued use of medical-necessity standards suggest an attempt to balance access with managed-care controls.
AB 669 would add new sections to the Health and Safety Code and Insurance Code governing substance use disorder coverage for commercial health plans and health insurers. It would restrict prior authorization, concurrent review, and retrospective review for certain in-network inpatient, residential, intensive outpatient, partial hospitalization, and outpatient prescription drug benefits, while requiring ASAM-based medical-necessity standards, expedited appeals, discharge planning, and limits on patient billing. The bill would not apply to Medi-Cal behavioral health delivery systems or Medi-Cal managed care plans, and it would take effect on January 1, 2027.
The bill appears to have received generally favorable treatment in policy committees and on the Assembly floor, with strong vote margins and no recorded committee opposition in some hearings. That pattern suggests broad support for improving access to substance use disorder treatment and limiting insurer utilization controls. However, the later Senate amendment cycle and the bill being held under submission indicate that concerns remained significant enough to slow advancement, likely around cost, implementation, and the effect on utilization review practices.
The central contention is the bill’s curtailment of health plan and insurer utilization management, especially the ban on concurrent and retrospective review during the first 28 days of certain treatment episodes and the prohibition on prior authorization for medically necessary outpatient SUD medications. Insurers and managed care plans may object that these limits reduce their ability to manage medical necessity and control costs, while supporters likely argue that such review practices can delay or interrupt clinically appropriate addiction treatment. A secondary point of contention is the bill’s detailed appeal and discharge rules, which could be seen as protecting patients from premature discharge but also as imposing administrative and operational burdens on facilities and plans.